RT Journal Article
T1 Salmonella enterica Serovar Typhimurium Exploits Inflammation to Modify Swine Intestinal Microbiota
A1 Drumo, Rosanna
A1 Pesciaroli, Michele
A1 Ruggeri, Jessica
A1 Tarantino, Michela
A1 Chirullo, Barbara
A1 Pistoia, Claudia
A1 Petrucci, Paola
A1 Martinelli, Nicola
A1 Moscati, Livia
A1 Manuali, Elisabetta
A1 Pavone, Silvia
A1 Picciolini, Matteo
A1 Ammendola, Serena
A1 Gabai, Gianfranco
A1 Battistoni, Andrea
A1 Pezzotti, Giovanni
A1 Alborali, Giovanni L
A1 Napolioni, Valerio
A1 Pasquali, Paolo
A1 Magistrali, Chiara F
AB Salmonella enterica serovar Typhimurium is an important zoonotic gastrointestinal pathogen responsible for foodborne disease worldwide. It is a successful enteric pathogen because it has developed virulence strategies allowing it to survive in a highly inflamed intestinal environment exploiting inflammation to overcome colonization resistance provided by intestinal microbiota. In this study, we used piglets featuring an intact microbiota, which naturally develop gastroenteritis, as model for salmonellosis. We compared the effects on the intestinal microbiota induced by a wild type and an attenuated S. Typhimurium in order to evaluate whether the modifications are correlated with the virulence of the strain. This study showed that Salmonella alters microbiota in a virulence-dependent manner. We found that the wild type S. Typhimurium induced inflammation and a reduction of specific protecting microbiota species (SCFA-producing bacteria) normally involved in providing a barrier against pathogens. Both these effects could contribute to impair colonization resistance, increasing the host susceptibility to wild type S. Typhimurium colonization. In contrast, the attenuated S. Typhimurium, which is characterized by a reduced ability to colonize the intestine, and by a very mild inflammatory response, was unable to successfully sustain competition with the microbiota.
PB Frontiers Media
SN 2235-2988
YR 2015
FD 2015
LK https://hdl.handle.net/20.500.14352/35264
UL https://hdl.handle.net/20.500.14352/35264
LA eng
NO Unión Europea. FP7
DS Docta Complutense
RD 13 jul 2025